



Siena, 07/07/21
Segreteria: 0577/586798
Reperto: 0577/586744
Fax: 0577/586185

RE: Manuscript ID 65275 revised manuscript (revision 1)

Dear Editor,

thank you for having invited us to submit a revised version of the manuscript ID 65275, formerly entitled “Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas” by Cencini et al. We have revised the manuscript and we have answered to all the questions made by the reviewers.

All modifications are indicated in the revised version of the text in red characters.
All authors included in the manuscript have agreed to re-submission. The manuscript has not been submitted elsewhere while under consideration for World Journal of Clinical Oncology. Please refer to me for any correspondence regarding this matter.
We hope that the manuscript is now suitable for publication in World Journal of Clinical Oncology. Again, I would like to thank you for the opportunity to submit an invited manuscript as review article for your journal.
All authors included in the manuscript have contributed to, read and approved its submission. All authors declare no conflicts of interest.

Sincerely yours,

Emanuele Cencini, MD, PhD
Unit of Hematology, University Hospital
Viale Bracci - 53100 Siena, Italy
tel: + 39 0577 586798, fax: + 39 0577 586185
e-mail: emanuele.cencini@ao-siena.toscana.it

Reviewer #1: Scientific Quality: Grade A (Excellent) Language Quality: Grade A (Priority publishing) Conclusion: Accept (General priority) Specific Comments to Authors: The review article written in proper manner with all the related information. The literature review was done extensively related to the review article. Written quality is good and readers friendly. The article is good for publication.

We would like to thank the reviewer for the positive comments.

LANGUAGE QUALITY

Please resolve all language issues in the manuscript based on the peer review report. Please be sure to have a native-English speaker edit the manuscript for grammar, sentence structure, word usage, spelling, capitalization, punctuation, format, and general readability, so that the manuscript's language will meet our direct publishing needs.

We have provided an English certificate by Filipodia, grade A.

EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

Science editor: 1. Scientific quality: This review summarizes the role of the specialty drug "lenalidomide" in the treatment of peripheral T-cell non-Hodgkin lymphomas. The topic is within the scope of the WJCO. (1) Classification: Grade A (a single Reviewer); (2) Summary of the Peer-Review Report: Peripheral T-cell lymphoma (TCL) is defined as a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer cells. It is classified as a subtype of non-Hodgkin's lymphoma. Lenalidomide is an oral drug with immunomodulatory, antiangiogenic and direct antineoplastic effects. This review summarizes current literature and concludes that lenalidomide could represent a suitable treatment option for relapsed/refractory TCL, especially for neoplasms with a T-follicular helper origin. The manuscript is well-written and easily comprehensible; (3) Format: There are 3 tables and 1 figure. Figure 1 is of good quality; however, the letters should be enlarged. All tables are well-structured and informative; (4) References: A total of 70 references are cited, including 17 references published in the last 3 years. The literature is well-reviewed; the authors have cited several important papers relevant to their study; (5) Self-cited references: There are 5 self-cited references. The self-referencing rate is less than 10%, which is acceptable; (6) References recommendations: The authors have the right to refuse to cite improper references recommended by the peer reviewer(s), especially those published by the peer reviewer(s) him/herself (themselves). If the authors find the peer reviewer(s) request for the authors to cite improper references published by him/herself (themselves), please send the peer reviewer's ID number to editorialoffice@wjgnet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately. 2. Language evaluation: Classification: Grade A (a single Reviewer). According to the Reviewer's report, written quality is good and friendly to the readers. The corresponding author has also provided a language editing certificate provided by a language editing company; 3. Academic norms and rules: A Conflict-of-Interest statement is included in the manuscript, according to

which there are no conflicts of interest to disclose; however, the authors did not provide the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. No academic misconduct was found by the Google/Bing search. 4. Supplementary comments: This is an invited manuscript. No financial support is mentioned. The topic has not previously been published in the WJCO. 5. Issues raised: (1) Please prepare and arrange the figure using PowerPoint to ensure that the graph or text portions can be reprocessed by the Editor; (2) Please provide the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. (3) Please add the year of publication in reference #14. 6. Re-Review: Not required. 7. Recommendation: Conditional acceptance.

First of all, we would like to thank the Editor for the positive comments. We have prepared and arranged the figure using PowerPoint system, as requested.

We have provided the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement for all the authors, as requested.

We have added the year of publication in reference #14, that is 2018, as showed below

- 14. Kim YH**, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncol* **2018**; **19**: 1192-1204 [PMID: 30100375 DOI: 10.1016/S1470-2045(18)30379-6]

(2) Company editor-in-chief: I have reviewed the Peer-Review Report, the full text of the manuscript, the relevant ethics documents, and the English Language Certificate, all of which have met the basic publishing requirements of the World Journal of Clinical Oncology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.

We would like to thank the Editor for the positive comments.